Drug Trial Radar · NCT03474965
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Oct 1, 2018
Primary completion
Nov 6, 2024
Study completion Nov 6, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 2 to \<18 years with a history of Vaso-Occlusive Crisis (VOC) with or without Hydroxyurea/Hydroxycarbamide (HU/HC), receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was previously demonstrated in adults with sickle cell disease. The approach was to extrapolate from the pharmacokinetics (PK)/pharmacodynamics (PD) already established in the adult population. The study was designed as a Phase II, multicenter, open-label study.
Conditions
- Sickle Cell Disease (SCD)
Interventions
CrizanlizumabDrug
Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): AUCd15 of Crizanlizumab After First Dose - Part ATime frame: Day 1 to Day 15
- Pharmacokinetics (PK) - AUCtau for Serum Crizanlizumab After Multiple Doses - Part A - Steady StateTime frame: Week 15 - Steady state
- Pharmacokinetics (PK) - Cmax for Crizanlizumab After First Dose and Multiple Doses - Part A - Steady StateTime frame: Week 1 (after first dose) and Week 15 (steady state)
- Pharmacodynamics (PD) - P-selectin Inhibition Parameters for Crizanlizumab After First Dose - Part A - AUCd15Time frame: Day 1 to Day 15
- Pharmacodynamics (PD) - P-selectin Inhibition Parameters for Crizanlizumab - Part A - AUCtau After Multiple Dose - Steady StateTime frame: Week 15 - Steady state
- Frequency of Any Adverse Events (AEs) as a Measure of Safety and TolerabilityTime frame: Adverse events are reported from the first dose of study treatment until end of study treatment Week 103 plus 105 days post-treatment follow-up, up to a maximum timeframe of approximately 2 years and 3.25 months.
Locations
35 sites in 14 countries. Site status is shown where the registry gives one.
University Of Alabama
Birmingham, Alabama
Childrens National Hospital
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
Joe DiMaggio Childrens Hospital
Hollywood, Florida
Childrens Healthcare of Atlanta
Atlanta, Georgia
Childrens Hosp Boston Dept of Hematology
Boston, Massachusetts
Childrens Hospital at Montefiore
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
East Carolina University
Greenville, North Carolina
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania
Medical Uni of South Carolina
Charleston, South Carolina
Cook Childrens Medical Center
Fort Worth, Texas
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Laken, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Ribeirão Preto, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montería, Colombia
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
Padova, PD, Italy
Novartis Investigative Site
Orbassano, TO, Italy
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
Tripoli, Lebanon
Novartis Investigative Site
Muscat, Oman
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Palma de Mallorca, Balearic Islands, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Adana, Turkey (Türkiye)
Novartis Investigative Site
Mersin, Turkey (Türkiye)
Novartis Investigative Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.